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Abstract
Background and purpose: The objectives were to assess the feasibility and validity of 
using markers of dementia-related health as indicators of dementia progression in pri-
mary care, by assessing the frequency with which they are recorded and by testing the 
hypothesis that they are associated with recognised outcomes of dementia. The markers, 
in 13 domains, were derived previously through literature review, expert consensus, and 
analysis of regional primary care records.
Methods: The study population consisted of patients with a recorded dementia diagnosis 
in the Clinical Practice Research Datalink, a UK primary care database linked to second-
ary care records. Incidence of recorded domains in the 36 months after diagnosis was de-
termined. Associations of recording of domains with future hospital admission, palliative 
care, and mortality were derived.
Results: There were 30,463 people with diagnosed dementia. Incidence of domains 
ranged from 469/1000 person-years (Increased Multimorbidity) to 11/1000 (Home 
Pressures). An increasing number of domains in which a new marker was recorded in the 
first year after diagnosis was associated with hospital admission (hazard ratio for ≥4 do-
mains vs. no domains = 1.24; 95% confidence interval = 1.15–1.33), palliative care (1.87; 
1.62–2.15), and mortality (1.57; 1.47–1.67). Individual domains were associated with out-
comes with varying strengths of association.
Conclusions: Feasibility and validity of potential indicators of progression of dementia 
derived from primary care records are supported by their frequency of recording and 
associations with recognised outcomes. Further research should assess whether these 
markers can help identify patients with poorer prognosis to improve outcomes through 
stratified care and targeted support.
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INTRODUC TION
Over 850,000 people in the UK are estimated to live with dementia, 
projected to rise to 1.6 million by 2040 [1]. Dementia has a substan-
tial impact on the lives of individuals. The UK government has pri-
oritised early recognition and treatment, to prolong independence, 
delay and reduce admissions to nursing homes and hospitals, and 
prolong survival [2–4]. Primary care has a pivotal role in achieving 
these aims [5–7], particularly in the UK, where most people are reg-
istered with a general practitioner (GP) and receive care for long-
term conditions.
There have been primary care studies on “case-finding” and 
identifying risk factors for dementia onset [8,9], but little research 
on the course and prognosis of patients with dementia in primary 
care. One potential source of information on the course of dementia 
is primary care electronic health records (EHR) that contain coded 
reasons (morbidities, symptoms) for consultation and management 
(for example, prescriptions, referrals, tests, investigations). Although 
EHR can provide data on “hard” long-term outcomes such as hospital 
admissions and mortality, it is not known whether indicators of dis-
ease progression can be identified from primary care EHR.
A set of indicators in primary care could support case manage-
ment decisions, contribute to understanding of prognosis, improve 
communication with patients and caregivers, and inform planning 
and monitoring of care at a population level. They could improve the 
efficiency of intervention studies, which currently rely on intensive 
and costly follow-up assessments and long-term outcomes such as 
mortality. In the first part of the Measurement of Dementia Disease 
Progression in Primary Care (MEDDIP) study, we established a set 
of markers of dementia-related health that may be recorded in UK 
primary care EHR [10], drawing on a rapid literature review, expert 
consensus, and scrutiny of a regional primary care EHR database. 
The set has 63 markers in 13 domains (Table 1).
The objectives of this part of the MEDDIP study were to assess 
the feasibility and validity of these markers and domains as indicators 
of progression for people with dementia. Feasibility was assessed by 
estimating the prevalence and incidence of recorded markers and 
domains within primary care EHR at the time of, and early after, di-
agnosis of dementia. Validity was assessed by estimating the asso-
ciation of recording of these domains with established longer-term 
outcomes (hospital admission, palliative care, early mortality) under 
the hypothesis (construct validity) that patients with new recorded 
markers/domains early on in their dementia course will have a higher 
risk of poor outcomes.
METHODS
Setting
This was a cohort study set within the Clinical Practice Research 
Datalink (CPRD) GOLD, a database of longitudinal pseudonymised 
primary care data from 17 million patients across a network of UK 
general practices. The study was approved by the CPRD Independent 
Scientific Advisory Committee (ref 19_002).
Study population
Patients with a recorded diagnosis of Alzheimer's disease, vascular 
dementia, Lewy body dementia, Parkinson's dementia, frontotem-
poral dementia, and mixed and unspecified dementia between 1998 
and 2017 were included. Diagnosis of dementia was based on a Read 
code list developed previously through consensus of GP and EHR 
researchers [11], and code lists used in other studies [12–14]. Read 
codes are the main method of recording morbidity and processes of 
care within UK primary care. Coding of dementia in UK primary care 
EHR has been validated previously [15]. Patients with a Read code 
suggesting a history of any type of dementia (for example, “H/O: 
(History of) dementia”, “Dementia annual review”) prior to the date 
of first dementia diagnosis (index date) or a recorded prescription 
for an antidementia drug (donepezil, galantamine, memantine, riv-
astigmine) prior to the index date were excluded. Read code lists are 
available at www.keele.ac.uk/mrr.
Patients had to have 3 years of up-to-standard data in CPRD 
prior to the index date and 1 year after index date as a minimum 
follow-up time to capture progression of dementia (Figure 1a). All 
patients were required to have linked Hospital Episode Statistics 
(HES) admissions, neighbourhood deprivation (Index of Multiple 
Deprivation 2015 [16]), and mortality (via the Office for National 
Statistics [ONS]) data. This encompasses around 50% of patients in 
CPRD GOLD (all in England).
Markers and domains
Code lists for markers utilised previous UK-based EHR research stud-
ies [17–24], existing databases of Read code lists [25,26], and searches 
of the UK Clinical Terminology Read Code Browser. The markers and 
associated domains are shown in Table 1. The first recording of each 
marker in the period from 2 years before the index date to 3 years after 
was identified. The exception was for the Increased Multimorbidity 
domain, which was measured for each 12-month period within those 
5 years and is a general measure of multimorbidity (increase in num-
ber of different drugs prescribed, based on British National Formulary 
sections, compared to the previous 12-month period). The Dementia-
Related Drug domain was based on a new prescribed drug specific to 
dementia (donepezil, galantamine, memantine, rivastigmine) or a drug 
that may be used in dementia as well as other conditions (levodopa, 
clonazepam, rotigotine, selegiline, rasagiline, apomorphine).
Outcomes
The outcomes were first all-cause hospital admission, palliative care, 
and all-cause mortality measured until the end of follow-up, defined 
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TA B L E  1  List of markers nested within domains with examples
Domain Marker Examples
Care Additional help Home help, day care
Care Carer Evidence has a carer in records
Care Shared decision-making Shared decision-making
Care Advanced directive Advanced care planning
Home Pressures Home pressures Marital problems, family bereavement/row
Severe Neuropsychiatric Severe mental illness – (a) coded Psychosis, schizophrenia
Severe Neuropsychiatric Severe mental illness – (b) medication Antipsychotic drug
Severe Neuropsychiatric Sectioned Sectioned form completed/fee paid
Severe Neuropsychiatric Crisis Mental crisis plan, referral to crisis team
Severe Neuropsychiatric Suicidal Suicidal, high/medium suicide risk
Neuropsychiatric Depression, anxiety, stress – (a) coded Depression, anxiety, stress
Neuropsychiatric Depression, anxiety, stress – (b) medication Antidepressant drug
Neuropsychiatric Aggressive behaviour Aggressive/abusive behaviour
Neuropsychiatric Sleep problems – (a) coded Insomnia, nightmares
Neuropsychiatric Sleep problems – (b) medication Hypnotic/anxiolytic drug
Neuropsychiatric Behavioural issues Behavioural problem, disinhibited behaviour
Neuropsychiatric Low mood Low mood, tearful, worried, lack of concentration
Neuropsychiatric Wandering Wanders during day/night
Cognitive Function Cognition Cognitive decline, mentally vague
Cognitive Function Memory loss Memory loss, amnesia, poor memory
Cognitive Function Confusion Confusion, delirium, disorientated
Cognitive Function Aphasia Aphasia, speech therapy/defect, stammer
Daily Functioning Bedbound Bedbound, bed-ridden
Daily Functioning Wheelchair Provision of/independent in wheelchair
Daily Functioning Severe mobility limitation Housebound, chairbound, Zimmer frame
Daily Functioning Mobility – less severe limitation Mobility poor, walking stick, gait abnormality
Daily Functioning Pressure sore Pressure sore, decubitus ulcer
Daily Functioning Driving Unfit to drive, advised about driving
Daily Functioning Difficulty in eating Eating problem, dependent for eating
Daily Functioning Difficulty handling finance Needs help handling financial affairs
Daily Functioning Personal care limitation Dependent for dressing/toilet/bathing
Daily Functioning Stairs limitation Difficulty managing stairs, need help on stairs
Safety Fall Recorded fall
Safety Fracture Recorded fracture (excluding skull)
Safety Intracranial injury Skull fracture, concussion
Safety Safety assessment Falls risk assessment, home safety advice
Comorbidity Cardiovascular Myocardial infarction, ischaemic heart disease
Comorbidity Stroke Stroke, cerebral infarction
Comorbidity Parkinson's disease Parkinson's disease
Comorbidity Motor neurone disease Motor neurone disease
Comorbidity Diabetes Diabetes mellitus (type I or II)
Comorbidity Epilepsy Epilepsy, grand mal/petit mal, fit frequency
Comorbidity Asthma/COPD Asthma, COPD, chronic bronchitis
Comorbidity Musculoskeletal pain Osteoarthritis, regional pain, rheumatoid arthritis
Comorbidity Anaemia Iron deficiency anaemia, vitamin B12 deficiency
(Continues)
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Domain Marker Examples
Comorbidity Ocular Cataract, retinopathy, glaucoma, blindness
Comorbidity Hypertension Essential hypertension, hypertensive disease
Comorbidity Candidiasis Candidiasis, thrush
Symptoms Dizziness Dizziness, vertigo, hypotension, giddiness
Symptoms Incontinence Incontinent of urine/faeces, urgency micturition
Symptoms Constipation/IBS Constipation, IBS
Symptoms Diarrhoea Diarrhoea, loose stools
Symptoms Urinary Retention of urine, haematuria, dysuria
Symptoms Neurological Fit (no epilepsy record), blackout
Symptoms Chest pain (noncardiovascular) Costochondritis, unspecified chest pain
Symptoms Oral health Stomatitis, poor oral hygiene, sore mouth
Symptoms Swallowing Difficulty swallowing liquids/solids, dysphagia
Symptoms Hearing loss Deafness, hearing loss/impairment
Symptoms “Feels unwell” Recorded "feels unwell"
Diet/Nutrition Poor diet Advice re diet, high fat diet, dietician referral
Diet/Nutrition Nutrition Vitamin/iron deficiency, osteomalacia
Diet/Nutrition Weight loss Weight decreasing/loss, underweight
Diet/Nutrition Dietary supplement Dietary supplement
Imaging Imaging X-ray, MRI, ECG, DXA, angiogram, CAT scan
Increased Multimorbidity Increase in polypharmacy Increase in count of different drugs prescribed
Dementia-Related Drug Change in dementia-related drug New or changed dementia drug prescribed
Note: Reproduced with permission from Campbell et al. [10]. © 2020 Taylor & Francis Group.
Abbreviations: CAT, computer-assisted tomography; COPD, chronic obstructive pulmonary disease; DXA, dual-energy X-ray absorptiometry; ECG, 
electrocardiogram; IBS, irritable bowel syndrome; MRI, magnetic resonance imaging.
TABLE 1 (Continued)
F I G U R E  1  Time windows for the study. m, months
 Time windows for the study
1a) Study population definitions
1b) Prevalence and incidence of markers and domains 
1c) Association of individual domains with outcomes
1d) Association of accumulation of markers post-diagnosis with outcomes
-36 to 0m: Look back period to remove prevalent pa	ents 0 to +12m: Minimum follow-up
Index date (diagnosis)
-24 to 0m: Prevalent markers/domains 0 to +36m: Incident markers/domains
Index date (diagnosis)
-24m to +36m: Exposed from first record of domain up to earliest of outcome, censoring, or 36m
Index date (diagnosis)
0m onwards: follow-up of outcomes un	l death, end of study, or end of records
0 to +12m: count of domains with first record of any marker not recorded in 24m pre-index date
Index date (diagnosis)
+12m onwards: follow-up of outcomes un	l death, end of study, or end of records
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as the earliest of date of death, end of study (31 December 2018), 
and date of end of up-to-standard records in CPRD. Hospital admis-
sion from any cause was based on recorded date of admission in the 
linked HES data after diagnosis. Palliative care was defined based on 
Read coded indication of palliative care or coded indication of being 
within 12 months of end of life [27]. Patients with such a Read code 
prior to the index date were excluded from analysis of this outcome. 
All-cause mortality was defined as the earliest record of death from 
CPRD or ONS mortality data.
Baseline covariates
Covariates were age at index date, sex, year of diagnosis, geo-
graphical region, deprivation, and lifestyle factors. Deprivation was 
measured by the Index of Multiple Deprivation 2015, a composite 
measure of neighbourhood deprivation [16]. Lifestyle factors (body 
mass index, smoking status, alcohol consumption) were based on the 
most recent measurement in the 5 years prior to the index date.
Analysis
Time periods for each analysis are shown in Figure 1. When analys-
ing associations with outcomes, markers and domains were meas-
ured prior to occurrence of that outcome.
Feasibility: prevalence and incidence of 
markers and domains
The prevalence of recorded markers at time of diagnosis, defined as 
the proportion of all people in the study population with a record of 
the marker in the 24 months prior to the index date, was determined. 
Incidence per 1000 person-years (py) at risk of recorded markers 
in the 36 months after the index date in those with no record of 
the marker in the 24 months prior to the index date was determined 
(Figure 1b). Prevalences and incidences of domains were also cal-
culated. Incidence was defined for 12 domains as a record of any 
marker in the domain after the index date with no previous record 
of any marker from that domain. For the remaining domain, a first 
increase in the number of different drugs prescribed in a 12-month 
period compared to the previous 12 months indicated increased 
multimorbidity.
Validity: associations of domains with outcomes
Associations of domains with outcomes were assessed in two ways. 
First, we examined the associations of individual domains recorded 
up to 3 years after diagnosis (but before outcome). The incidence 
after the index date of each of the outcomes (hospital admission, 
palliative care, mortality) per 1000 py at risk was calculated. Cox 
proportional hazards models estimated the association of having any 
recorded marker in a domain with each outcome, adjusted for age and 
gender. The proportional hazards assumption was visually assessed 
using (log–log transformed) survival curves. Domain (exposure) was 
included as a time-varying covariate. Follow-up started at the index 
date, baseline exposure was defined as a record of any marker within 
the domain in the 24 months prior to the index date, and exposure 
status could change from unexposed at baseline to exposed over the 
first 3 years of follow-up (Figure 1c). It was assumed that once the pa-
tient was exposed (i.e., had a record of any marker from that domain), 
they were exposed for the remainder of follow-up (until censored or 
outcome occurred). As Increased Multimorbidity was defined over a 
12-month period, date of changed exposure was the end of the 12-
month period, that is, 1, 2, or 3 years after the index date.
Validity: accumulation of markers and association 
with outcomes
Our second approach to examine associations of domains with 
outcomes assessed the relationship of accumulation of new mark-
ers early after diagnosis with outcomes. For this analysis, for most 
domains, a record of any previously unrecorded marker in a domain 
indicated progression even if another marker within that domain 
had previously been recorded. The Daily Functioning domain has a 
hierarchical subset of markers (Mobility-Limited, Mobility-Severe, 
Wheelchair, Bedbound), and a marker was counted only if a more re-
stricted mobility marker had not previously been used. In the Safety 
domain, any fall was counted regardless of previously recorded falls. 
For each patient, we determined the cumulative number of domains 
with at least one marker that was first recorded in the 12 months 
after the index date (i.e., no record of that marker in the 24 months 
prior to the index date, even if other markers in that domain had 
been recorded). Follow-up of outcomes started at 12 months after 
the index date (Figure 1d). Cox proportional hazards models de-
termined the association of cumulative number of domains in that 
first 12 months with the outcomes adjusted for baseline covariates. 
Analysis was repeated for cumulative number of domains over the 
36 months after the index date in those with at least 36 months 
of follow-up, with follow-up of outcomes starting at 36 months. 
Robustness of estimates was assessed by repeating the analysis 
using flexible parametric models.
Sensitivity analyses assessed whether any improvement in com-
pleteness of recording of markers over time influenced results by 
restricting the analysis to patients diagnosed with dementia from 
2010 onward.
All analyses were performed in Stata v15.
RESULTS
A total of 30,463 patients with dementia met our inclusion criteria. 
Baseline patient characteristics are given in Table 2. Mean age was 
1504  |    RATHOD-MISTRY eT Al.
81.6 (SD = 7.86) years, and 63% were female. Median follow-up was 
2.73 (interquartile range = 1.75–4.24) years. The majority (96% of 
those with a type recorded) of dementia patients were diagnosed 
with Alzheimer's or vascular dementia.
Prevalence and incidence of markers and domains
In the 24 months prior to index (diagnosis) date, 68% of patients had 
at least one recorded marker from the Comorbidity domain and 62% 
from the Cognitive Function domain (Table 3). Home Pressures (4%) 
and Care (5%) were the least prevalent domains.
Increased Multimorbidity (based on increase in polypharmacy) 
was the most common domain newly recorded after the index date. 
The highest incidence for the other domains was observed for 
Comorbidity (300/1000 py) and Symptoms (230/1000 py). Home 
Pressures had the lowest incidence (11/1000 py). Prevalence and 
incidence of markers are reported in Table S1.
Associations of domains with outcomes
Seventy-four percent of patients were hospitalised at least once 
after the index date (430/1000 py; 95% confidence interval [CI] = 
424–436), 8% of patients received palliative care (26/1000 py; 95% 
CI = 25–27), and 37% of patients died (115/1000 py; 95% CI = 112–
116) during follow-up.
The majority of domains were associated with increased risk of 
all three outcomes (Table 4). The Safety, Comorbidity, and Symptoms 
domains had the strongest associations with hospital admission (haz-
ard ratios [HRs] = 1.36–1.40), whereas the Severe Neuropsychiatric, 
Diet/Nutrition, Increased Multimorbidity, and Daily Functioning 
domains had the strongest associations with palliative care (HRs = 
1.97–2.23) and mortality (HRs = 1.92–2.84). The Home Pressures 
domain was only associated with palliative care. The Cognitive 
Function domain was negatively associated with hospital admission 
(HR = 0.94; 95% CI = 0.91–0.97) and mortality (HR = 0.95; 95% CI = 
0.92–0.99). A new or change in dementia-related drug was protec-
tive of all three outcomes.
Accumulation of markers and association 
with outcomes
In the 12 months after the index date, 26,055 (86%) patients had 
at least one recorded marker not previously recorded, and 5594 
(18%) had at least four domains with a new recorded marker. 
Increasing number of domains with new recorded markers in the 
1 year after the index date was linearly associated with increasing 
risk of hospital admission, palliative care, and mortality (Table 5). 
Adjusted HRs when comparing patients with new markers in four 
or more domains to patients with no new recorded markers were 
1.24 (95% CI = 1.15–1.33) for hospital admission, 1.87 (95% CI = 
TA B L E  2  Characteristics of patients with dementia, n = 30,463
Characteristic n (%)a 
Age







Lewy body 478 (1.6)
Parkinson's 262 (0.9)
Frontotemporal 48 (0.2)





Not recorded 8946 (29.4)
Smoking status
Nonsmoker 13,888 (45.6)
Current smoker 3042 (10.0)
Ex-smoker 8493 (27.9)
Not recorded 5040 (16.5)
Alcohol consumption
Nondrinker 4743 (15.6)
Current drinker 11,712 (38.5)
Ex-drinker 987 (3.2)
Not recorded 13,021 (42.7)






Yorkshire & the Humber 1191 (3.9)
East Midlands 751 (2.5)
West Midlands 3958 (13.0)
East of England 3287 (10.8)
Southwest 4133 (13.6)
South central 4079 (13.4)
London 2954 (9.7)
Southeast coast 4225 (13.9)
Deprivation




5, most deprived 4585 (15.1)
aUnless otherwise stated. 
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1.62–2.15) for palliative care, and 1.57 (95% CI = 1.47–1.67) for 
mortality. Restricting analysis to the 15,123 patients diagnosed 
with dementia from 2010 onward gave similar strengths of asso-
ciation (Table S2).
Sensitivity analysis exploring the associations between domains 
recorded in the 3 years after the index date with outcomes after 
3 years provided similar results. HRs for the comparison of patients 
with four or more domains with newly recorded markers compared 
to those with no domains were 1.28 (95% CI = 1.05–1.57) for hospi-
tal admission, 2.31 (95% CI = 1.27–4.19) for palliative care, and 1.64 
(95% CI = 1.33–2.03) for mortality (Table S3). Repeating the main 
analyses using flexible parametric models yielded similar HRs to the 
Cox proportional hazards models (Table S4).
DISCUSSION
This study of more than 30,000 patients with dementia in England 
aimed to determine the feasibility and validity of using markers of 
dementia-related health as indicators of dementia progression in 
primary care. The study showed that these markers, nested in do-
mains, can be identified in primary care EHR, and their recording is 
associated with recognised endpoint outcomes (hospital admission, 
palliative care, mortality). There was a dose–response effect after 
diagnosis, with an increase in risk of poor outcomes as the number of 
domains for which new markers were recorded soon after diagnosis 
increased. These results demonstrate the potential to identify indica-
tors of progression for those with dementia using primary care EHR.
Although there was variation in their prevalence and incidence, all 
domains had evidence of regular recording in primary care. However, 
some individual markers were infrequently recorded and use of these 
markers as indicators of progression may be more feasible at the 
domain level. Construct validity of the domains was shown through 
testing of an a priori hypothesis of their association with recognised 
outcomes. A record of a marker such as psychosis within the Severe 
Neuropsychiatric domain increased risk of all outcomes, concordant 
with a previously identified link of behavioural and psychological 
symptoms and/or antipsychotic use with risk of hospitalisation, nursing 
home admission, and mortality [28–31]. The Increased Multimorbidity, 
Comorbidity, and Symptoms domains were commonly recorded and 
strongly associated with the outcomes, supporting reviews showing 
increases in comorbidity and health-related burden related to poor 
dementia outcomes [30,32,33]. The Care domain showed associations 
across all outcomes; research shows that caregiver coping and stress 
is associated with poor outcomes in the person with dementia [30,34], 
but also will be reflective of increased provision of care as demon-
strated by the strong association with palliative care.
Having a record of a marker (e.g., cognitive decline or memory 
loss) from the Cognitive Function domain did not increase risk of the 
outcomes. One explanation for this might be the level of informa-
tion available. A recent EHR study interrogated narrative text (i.e., 
clinical notes) to give a gradient of cognitive function severity and 
demonstrated that greater severity is associated with mortality [35]. 
A finer grade indicator inclusive of severity would be beneficial in 
the prediction of outcomes. It is also possible cognitive function is 
less commonly assessed or completed when the patient is nearing 
end of life [36], or that noncognitive measures are more strongly as-
sociated with the outcomes used here.
A prescription for a new dementia-related drug was associated 
with a reduced risk of the outcomes. Previous research has shown 
Domain
Prevalence 
in 24 months 
before index date
Incidencea  per 1,000 person-years in 
36 months after index date
n (%) n (%)b  Incidence (95% CI)
Care 1432 (4.7) 5567 (19.1) 88.17 (85.89–90.52)
Home Pressures 1178 (3.9) 775 (2.7) 11.24 (10.48–12.06)
Severe Neuropsychiatric 3145 (10.3) 5068 (18.6) 85.64 (83.31–88.03)
Neuropsychiatric 13,834 (45.4) 5922 (35.6) 186.36 (181.68–191.17)
Cognitive Function 18,979 (62.3) 3099 (27.0) 136.78 (132.05–141.68)
Daily Functioning 2558 (8.4) 4684 (16.8) 76.45 (74.30–78.68)
Safety 7177 (23.6) 6617 (28.4) 137.93 (134.65–141.29)
Comorbidity 20,555 (67.5) 4919 (49.7) 299.93 (291.67–308.43)
Diet/Nutrition 5388 (17.7) 5971 (23.8) 112.41 (109.59–115.29)
Symptoms 13,921 (45.7) 6933 (41.9) 230.47 (225.11–235.96)
Imaging 14,659 (48.1) 5481 (34.7) 185.56 (180.72–190.54)
Increased Multimorbidity 12,501 (41.0) 13,696 (76.3) 468.54 (460.76–476.45)
Dementia-Related Drug 1623 (5.3) 10,335 (35.8) 206.65 (202.71–210.67)
aIncidence defined as first record of any marker within domain, in those with no marker from that 
domain recorded in 24 months prior to index date. 
bIn those with no record of domain in 24 months before index date. 
TA B L E  3  Prevalence and incidence of 
recorded domains
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that use of cholinesterase inhibitors is associated with lower mor-
tality in people living with Alzheimer's disease [37,38]. This domain 
does not take into account reason for change or whether change 
was to a more or less potent drug (related to stage of dementia) and 
therefore may be a less valid indicator of progression.
The domains of Daily Functioning, Diet/Nutrition, and Safety 
showed consistent associations with our outcomes, which concurs 
with research that has shown associations between functional abil-
ity and mortality [39], and nutrition and outcomes for those with 
dementia [40], and is reflective of broader function, safety issues 
(e.g., falls), and frailty in elderly populations [41,42].
Strengths and limitations
This study tested a rigorously developed set of domains previously 
demonstrated to be associated with dementia. These domains had 
been produced via a review of EHR dementia research and expert 
consensus to ensure clinical relevance, mapped to an internation-
ally agreed set of outcomes [43], and initial testing within a regional 
EHR database [10]. The CPRD database is broadly reflective of the 
UK population [44] with established validity for coding and accuracy 
of dementia diagnosis [45]. Although measures of frailty designed 
for use within EHR for the elderly population [41] may overlap with 
some of the domains, we have derived domains specifically relevant 
to dementia. Future studies could compare our indicators of early 
progression with general measures of frailty.
Lewy body and frontotemporal dementia are associated with 
greater behavioural disturbance and have a faster progression rate 
to mortality [46,47]. Given these types of dementia are less common, 
larger studies should compare indicators of progression by dementia 
type. Whereas a person may consult with a number of problems, the 
clinician might decide to only code one problem. A coded record for 
a marker would suggest this was a key reason for a consultation and 
of importance to the clinician and patient/caregiver. Some markers 
may have been recorded prior to the window of time we examined, 
and although most chronic problems should be entered on a regu-
lar basis, our markers reflect recent issues. It is possible that some 
markers in a domain may be acute in nature and have less impact 
on long-term outcomes. Some markers could be sequentially related 
(e.g., a fall before a fracture), or have a gradient of severity (e.g., neu-
ropsychiatric). This study aimed to determine the validity of markers 
and domains as indicators of progression, and not as independent 
predictors of poor outcome. As such, some of the associations iden-
tified with long-term outcomes may have arisen through chance 
given the multiple testing, and there may be other factors predictive 
of poor outcome, including socioeconomic status, ethnicity, social 
support, and social care provision [24,30,32,33,48,49], and mea-
sures obtainable by invasive testing such as pathogen presence (e.g., 











0 3540 2216 (62.6) 1.00 1.00
1 5702 3350 (58.8) 0.99 (0.94–1.05) 1.03 (0.97–1.08)
2 4672 2797 (59.9) 1.06 (1.00–1.13) 1.09 (1.03–1.16)
3 2838 1711 (60.3) 1.13 (1.05–1.22) 1.16 (1.07–1.25)
4+ 2353 1375 (58.4) 1.20 (1.12–1.29) 1.24 (1.15–1.33)
Palliative carec 
0 4353 285 (6.6) 1.00 1.00
1 7725 528 (6.8) 1.14 (0.99–1.31) 1.11 (0.96–1.28)
2 7243 554 (7.6) 1.31 (1.14–1.51) 1.28 (1.11–1.47)
3 5152 410 (7.0) 1.48 (1.25–1.74) 1.44 (1.22–1.69)
4+ 5411 502 (9.3) 1.96 (1.70–2.26) 1.87 (1.62–2.15)
Mortality
0 4408 1632 (37.0) 1.00 1.00
1 7839 2731 (34.8) 1.01 (0.96–1.07) 1.05 (0.99–1.11)
2 7369 2731 (37.1) 1.11 (1.05–1.18) 1.16 (1.09–1.23)
3 5253 2040 (38.8) 1.24 (1.16–1.33) 1.26 (1.18–1.36)
4+ 5594 2394 (42.8) 1.56 (1.46–1.67) 1.57 (1.47–1.67)
Abbreviations: CI, confidence interval; HR, hazard ratio.
aHR adjusted for age, gender, body mass index, smoking status, alcohol consumption, deprivation, 
year of index date, and geographical region. 
bExcludes those with record of hospitalisation in the 12 months after index date. 
cExcludes those with record of palliative care in 24 months before index date or in the 12 months 
after index date. 
TA B L E  5  Association of the cumulative 
number of domains with new recorded 
markers in the first year after diagnosis 
with hospital admission, palliative care, 
and mortality after the first year
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resonance imaging). Future prognostic research should assess which 
domains improve prediction of long-term outcomes when added to 
other factors. Such research would need to address the potential 
for collinearity between domains. We could not use care home ad-
mission as an outcome, as this is not comprehensively recorded in 
primary care EHR. Future studies could compare recording of these 
markers and domains with changes on instruments designed to mea-
sure cognitive function such as the Mini-Mental State Examination, 
commonly used in secondary care dementia services.
Clinical relevance
This study is a key step in the development of an approach for manag-
ing people with dementia, where individuals who are at increased risk 
of a poor health outcome can be identified in a primary care setting. 
This has potential advantages. First, good information on prognosis can 
contribute to shared decisions on care between patients, carers, and 
clinicians. Second, “dementia” often overshadows other comorbidities 
within the consultation [50,51], and systematic information about such 
additional concerns contributes to more holistic approaches to care 
[52,53] and better health care coordination. Third, early identification 
and targeted care using a stratified-risk approach within the primary 
care population with dementia may offer the possibility of intervening 
to slow progression. This may be either by concentrating resources on 
patients with higher risk of poor outcomes or, if these markers and do-
mains can be shown to be independent predictors of poor outcome, by 
targeting those that are modifiable such as prescribing.
The increase in risk as number of domains with new markers in-
creases suggests that, although some domains had stronger asso-
ciations with outcomes than others, it is the cumulative burden of 
indicators rather than particular combinations that increases risk of 
poor outcomes. This may advocate a simple approach to monitor-
ing early dementia progression based on count of new indicators as 
measured by our domains.
These indicators may be useful in prognostic models to improve 
identification of patients with a poorer long-term outcome. It may 
be possible in the future to use these EHR-recorded markers and 
domains as short-term outcomes, reducing the time and costs of re-
search studies, given that dementia observational and intervention 
studies often have to use long-term outcomes such as mortality and 
care home admission.
CONCLUSIONS
The validity of potential indicators of progression of dementia de-
rived from primary care EHR is supported by their association with 
recognised outcomes. In particular, early accumulation of these indi-
cators after diagnosis is associated with hospital admission, palliative 
care, and mortality. Combined with their prevalence and incidence in 
primary care EHR that illustrate their potential feasibility for use in 
practice, our study has established a case for future investigation of 
whether this set of markers can be applied to identify patients with 
a poorer long-term prognosis to improve their outcomes through 
stratified care and targeted support.
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